Almac Group Awarded six 2024 CDMO Leadership Awards

Almac Group, the global contract development and manufacturing organisation, is delighted to announce that the Group’s Pharma Services and Sciences divisions have, once again, been recognised in all six core categories in this year’s CDMO Leadership Awards programme.

The annual award programme, presented by Outsourced Pharma and Life Science Leader, recognises top performing CDMOs, celebrating outstanding companies in drug development and manufacturing, emphasising high standards of quality, integrity and innovation exemplified in their work. Results are based solely on primary market research by Industry Standard Research (ISR), with winners in each category judged by their customers as either exceeding expectations or as top performers in outsourced projects conducted within the past 18 months.

Almac holds an exceptional record of client service, further underscored by the CDMO Leadership Awards programme and its primary research-driven methodology. The company is a privately owned and independent CDMO that has grown organically for over five decades, now employing over 7,200 and undergoing significant expansion in capacity and technology exceeding £400 million across the globe.

This year, 98 contract manufacturers were assessed by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. This experiential feedback was analysed by sponsor company size to reveal leading CDMOs in different performance categories.

Almac was successful in achieving awards in all core categories including:

• Capabilities (Small Pharma)
• Compatibility (Small Pharma)
• Expertise (Small Pharma)
• Quality (Small Pharma)
• Reliability (Overall, Small Pharma)
• Service (Small Pharma)

John McQuaid, President and Managing Director, Almac Pharma Services, commented: “Our mission is to advance human health by providing high quality, end-to-end solutions to our clients and ultimately their patients. Receiving recognition, for yet another year, demonstrates our commitment to excellence in pharmaceutical development and commercial supply services and is particularly significant as we have been assessed by our valued clients.”

Stephen Barr, President and Managing Director, Almac Sciences, added: “Once again, I am delighted and proud that Almac has been recognised by our clients via the Life Sciences CDMO awards. To win in all six categories further endorses our excellence in research, development and manufacturing of high-quality chemical products used in high-profile consumer industries across the globe. We will continue to drive innovation to deliver exceptional science, sophisticated technology and unparalleled expertise.”

Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma said: “Drug and therapy sponsors had much to be concerned with the last 12 months or so. There was still supply-chain uncertainty, ever-growing novelty in platforms and processes requiring new skillsets and technologies, and the speed of everything seemed to accelerate. Through it all, CDMOs stayed focused, and also adapted to customer and market needs. Those best at serving their customers (and thus patients) are recognized as the 2024 CDMO Leadership Award winners. CDMOs may not have had all the answers in an uncertain year, but these are the external partners who provided the biopharma industry with the best solutions.”

The company has just announced the completion of two new purpose-built facilities to expand its commercial manufacturing and packaging as well as peptide production as part of its ongoing global expansion investment programme.